Hepatitis B Virus News and Research

RSS

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

New BARACLUDE (entecavir) data presented demonstrated a continued low incidence of resistance in nucleoside-naïve patients through five years of treatment. In the nucleoside-naïve chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108).

25 Mar 2008

Fast food and no exercise damages the liver

Too much fast food and too little exercise can harm the liver, reveals a small study published ahead of print in the journal Gut.

18 Feb 2008

Extra-hepatic manifestation of hepatitis C virus infection

In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV).

17 Jan 2008

Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer

As the incidence of liver cancer continues to grow - fueled in large part, by rising rates of hepatitis C infections - so too does the need for tests to help diagnose the disease at an earlier stage.

16 Jan 2008

A look at China's most innovative health biotechnology companies

Government funds innovation but venture capital needed; Wary investors 'need to be shown the exits'; Returning 'sea turtles' bring expertise, international credibility

8 Jan 2008

Gene variation increases risk of liver tumor in patients with cirrhosis

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death.

2 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Optimal therapy for U.S. hepatitis C patients

As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.

28 Dec 2007

Raised public awareness of hepatitis C leads to 10 per cent increase in diagnoses

The number of newly diagnosed cases of hepatitis C infection in England reached 8,346 in 2006 - 10% higher than in 2005 - according to latest figures released by the Health Protection Agency (HPA).

17 Dec 2007

Treating patients with psychiatric disorders for hepatitis C

People with severe mental illnesses are far more likely to be infected with Hepatitis C virus compared to the general population, however, they often do not get treatment for their liver disease because current antiviral therapies have known psychiatric side effects.

4 Dec 2007

New upper limit defined for normal ALT in adolescent males

A new cohort study of adolescent offenders in Australia has identified an upper limit for alanine aminotransferase (ALT) that is more sensitive for the diagnosis of liver disease.

4 Dec 2007

Vaccination against hepatitis B does not seem to increase the risk of a first episode of MS in childhood

Vaccinating against the hepatitis B virus does not appear to be associated with the risk of developing multiple sclerosis in childhood, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

4 Dec 2007

New drug, eltrombopag boosts platelets in hepatitis C patients

It's not a cure, but this may be some of the best news patients infected with the hepatitis C virus (HCV) have heard in a long time: A new drug, eltrombopag, appears to be effective in boosting low platelet counts, one of the major reasons why patients can't endure antiviral treatments.

29 Nov 2007

Most UK citizens susceptible to hep B infection

The failure of the UK to introduce universal hepatitis B immunisation means that most UK citizens are susceptible to infection, warns an infectious diseases expert in this week's BMJ.

13 Nov 2007

Hepatitis C treatment reduces the virus but serious liver problems may progress

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon.

6 Nov 2007

Hepatitis C virus found to spread directly from cell to cell by-passing antibodies

Scientists looking for an effective treatment for Hepatitis C may face an even bigger task than anticipated. Recent studies looking into how the virus spreads in liver tumour cells have demonstrated that the virus uses two different routes, which may explain why the body's natural occurring antibodies are ineffective at controlling the virus.

5 Nov 2007

Is it pancreatitis in acute abdominal pain in acute viral hepatitis?

Hepatitis viruses have a strong tropism for hepatocytes; viral antigen also has been detected in pancreas and gallbladder.

1 Nov 2007

Strong association between tattoos and hepatitis C virus infection

The connection between tattoos and hepatitis C virus (HCV) has long been suspected but never completely substantiated.

22 Oct 2007

New virus drug will have to shoot at moving targets

The reproduction of

22 Oct 2007

New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

A team of researchers led by biologists at the University of California, San Diego has discovered a completely new mechanism that mammalian cells employ to fight infections of the Hepatitis C virus, which affects approximately 2.7 million Americans and 170 million people worldwide.

18 Oct 2007